Cargando…

Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials

INTRODUCTION: Asian patients with type 2 diabetes (T2D) are younger, leaner, and more likely to develop renal dysfunction than White populations. In this multiethnic analysis of data from phase 3 trials, we investigated the efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ning, Guang, Bandgar, Tushar, Hehnke, Uwe, Lee, Jisoo, Chan, Juliana C. N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599450/ https://www.ncbi.nlm.nih.gov/pubmed/28819835 http://dx.doi.org/10.1007/s12325-017-0595-7

Ejemplares similares

The clinical application of linagliptin in Asians
por: Cao, Chu-qing, et al.
Publicado: (2015)

2681. Outcomes Related to Respiratory Viral Infections in Cancer Patients on PD-1 Inhibitors
por: Khawaja, Fareed, et al.
Publicado: (2019)

Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin–angiotensin system inhibitors in type 2 diabetic patients with albuminuria
por: Cooper, Mark E., et al.
Publicado: (2019)

Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial
por: Ma, Ronald CW, et al.
Publicado: (2017)

Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial
por: Chen, Yuhong, et al.
Publicado: (2015)

2681. National Outpatient Sexually Transmitted Infection Testing in Pregnant Patients in the United States, 2012 to 2019
por: Strey, Kelsey, et al.
Publicado: (2023)

Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials
por: von Eynatten, Maximilian, et al.
Publicado: (2013)

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
por: Rosenstock, Julio, et al.
Publicado: (2015)

Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes
por: Sarashina, Akiko, et al.
Publicado: (2016)

Renal endocrinology: The new frontier
por: Sahay, Manisha, et al.
Publicado: (2012)

The sun, the moon, and renal endocrinology
por: Kalra, Sanjay, et al.
Publicado: (2012)

Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment
por: Guedes, Erika Paniago, et al.
Publicado: (2013)

Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA(®) Trial
por: Watada, Hirotaka, et al.
Publicado: (2020)

Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity
por: Kern, Matthias, et al.
Publicado: (2012)

Linagliptin: from bench to bedside
por: Doupis, John
Publicado: (2014)

Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations
por: Ceriello, Antonio, et al.
Publicado: (2016)

Bone mineral density and factors influencing it in Asian Indian population with type 2 diabetes mellitus
por: Kamalanathan, Sadishkumar, et al.
Publicado: (2014)

Novel Specific Metallo-β-Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM-Positive Enterobacterales
por: Zalacain, Magdalena, et al.
Publicado: (2021)

PB2681: GAPS IN THE ASSESSMENT AND MONITORING OF CARDIOVASCULAR RISK AND PSYCHOLOGICAL BURDEN IN POLYCYTHEMIA VERA: LANDMARK 2.0: A WORLDWIDE HEALTH SURVEY
por: Harrison, Claire, et al.
Publicado: (2023)

Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I–III clinical trials
por: Yabe, Daisuke, et al.
Publicado: (2018)

Biological Safety Studies and Simultaneous Determination of Linagliptin and Synthetic Impurities by LC-PDA
por: Heleno Ferreira, Raquel Balestri, et al.
Publicado: (2019)

Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin
por: Zeng, Yi-Hong, et al.
Publicado: (2022)

A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting
por: Sanyal, Debmalya, et al.
Publicado: (2013)

Incorrect description of mode of excretion of linagliptin
por: Woerle, Hans-Juergen, et al.
Publicado: (2010)

Acute Kidney Injury Associated with Linagliptin
por: Nandikanti, Deepak K., et al.
Publicado: (2016)

Linagliptin-Associated Alopecia and Bullous Pemphigoid
por: Someili, Ali, et al.
Publicado: (2019)

Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials
por: Davidson, Jaime A, et al.
Publicado: (2014)

Analytical Enantio-Separation of Linagliptin in Linagliptin and Metformin HCl Dosage Forms by Applying Two-Level Factorial Design
por: Jadhav, Sushant B., et al.
Publicado: (2016)

Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin
por: Gallwitz, Baptist
Publicado: (2015)

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment
por: Groop, P-H, et al.
Publicado: (2014)

Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study
por: Yamamoto, Fumiko, et al.
Publicado: (2020)

Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function
por: Shigiyama, Fumika, et al.
Publicado: (2016)

Risk stratifying the screening of Barrett's esophagus: An Asian perspective
por: Sharma, Neel, et al.
Publicado: (2017)

Prevalence and Impact of Thyroid Disorders on Maternal Outcome in Asian-Indian Pregnant Women
por: Nambiar, Vimal, et al.
Publicado: (2011)

Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice
por: Hansen, Henrik H., et al.
Publicado: (2021)

Renal manifestations of primary hyperparathyroidism
por: Lila, Anurag Ranjan, et al.
Publicado: (2012)

Empagliflozin as add‐on to linagliptin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52‐week, randomized, placebo‐controlled trial
por: Kawamori, Ryuzo, et al.
Publicado: (2018)

Linagliptin as add‐on to empagliflozin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two‐part, randomized, placebo‐controlled trial
por: Kaku, Kohei, et al.
Publicado: (2018)

Clinical utility and tolerability of linagliptin in diabetic patients
por: Maxwell, Lauralee Gordon, et al.
Publicado: (2013)

Repositioning of Hypoglycemic Drug Linagliptin for Cancer Treatment
por: Li, Yong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sl96tq489hlfd6fcau4pkpmm8s